Release Date:  September 14, 1999

PA NUMBER:  PAS-99-166

National Institute of Diabetes and Digestive and Kidney Diseases



This Program Announcement (PA) solicits research to expand our understanding
of the underlying metabolic, genetic, epidemiologic, sociocultural, and
behavioral mechanisms that contribute to the racial and ethnic differences in
the etiology of type 2 diabetes mellitus in the United States.


The Public Health Service (PHS) is committed to achieving the health promotion
and disease prevention objectives of "Healthy People 2000," a PHS-led national
activity for setting priority areas.  This PA, Racial and Ethnic Differences
in the Etiology of Type 2 Diabetes in the United States, is related to the
priority area of diabetes.  Potential applicants may obtain a copy of "Healthy
People 2000" at http://odphp.osophs.dhhs.gov/pubs/hp2000/.


Applications may be submitted by domestic for-profit and non-profit
organizations, public and private, such as universities, colleges, hospitals,
laboratories, units of State and local governments, and eligible agencies of
the Federal Government.  Racial/ethnic minority individuals, women, and
persons with disabilities are encouraged to apply as principal investigators.


This PA will use the National Institutes of Health (NIH) research project
grant (R01) award mechanism.  Responsibility for the planning, direction, and
execution of the proposed project will be solely that of the applicant.  The
total project period for an application submitted in response to this PA must
not exceed 5 years.  Applications requesting $250,000 or less in direct costs
in any budget period must be prepared using Modular Grant and Just-in-Time
concepts.  Specific application instructions have been modified to reflect
"MODULAR GRANT" and "JUST-IN-TIME" streamlining efforts being examined by the
NIH. Complete and detailed instructions and information on Modular Grants can
be found at https://grants.nih.gov/grants/funding/modular/modular.htm.


For FY 2000, approximately $2 million will be committed to fund applications
submitted in response to this PA.  It is anticipated that six to eight awards
will be made.  For FY 2001 and FY 2002, approximately $2 million will be
committed each year to fund six to eight applications per year submitted in
response to this PA.  Funding is dependent on the receipt of a sufficient
number of applications of high scientific merit and on the availability of
funds for this purpose.  Applications on this topic submitted after October
2001 (potentially fundable in FY 2003) will be considered for funding in the
general NIDDK research project grant competition.



It is well recognized that there are major differences in the prevalence of
type 2 diabetes among race-ethnic groups in the United States.  Substantial
progress has been made toward identifying population-based risk factors for
the development of type 2 diabetes that might lead to these race-ethnic
disparities.  Such established risk factors include, for example, genetic
predisposition, total and central obesity, duration of obesity, high caloric
intake, and physical inactivity.  Factors such as socioeconomic status,
acculturation, and stress may also be important.  Individuals who have
progressed along the pathogenic course toward diabetes are at higher risk of
developing overt disease, and these individuals include those with insulin
resistance, impaired glucose tolerance, gestational diabetes, and reduced beta
cell function.

Although these diabetes risk factors appear to operate in all race-ethnic
groups, it is not known whether specific groups are inherently different in
the ways they respond to risk factors, which may lead to their differential
susceptibility to diabetes.  Environmental, genetic, and metabolic differences
may underlie the disparity in diabetes rates, and physiological outcomes of
risk factors may arise from a complex interplay of genetic and nongenetic
(behavioral, lifestyle, and environmental) factors.

Epidemiologic studies have documented the differing risk for diabetes among
race-ethnic groups and have established the identity of diabetes risk factors. 
However, with few exceptions, these studies have not been designed to examine
in depth the metabolic and physiologic effects of diabetes risk factors in
specific race-ethnic populations.  Consequently, there is an important need
for carefully designed clinical studies to investigate these issues in
representative samples of the various U.S. race-ethnic groups.

Objectives and Scope

The overall objective is to determine, through studies in representative U.S.
populations, the reasons for disparities in the incidence of type 2 diabetes
in minority race-ethnic populations.  Additionally, information which could
emerge from these studies would be important for devising cost-effective
approaches to phenotyping patients with type 2 diabetes and individuals at
risk for this disease.  The ability to characterize and identify discrete
subgroups of type 2 diabetes would be essential in genetic studies of this
disease.  Appropriate topics for investigation would include but are not
limited to:

o State-of-the-art, hypothesis-driven metabolic studies in which fat
metabolism, glucose levels, insulin secretion, energy expenditure, etc., are
measured in representative samples of U.S. race-ethnic groups.  Such studies
might determine, for example, whether some groups are at greater risk for type
2 diabetes from insulin resistance or from reduced beta-cell reserve; whether
fat content and distribution differ among race-ethnic groups, even if
lifestyle and socioeconomic factors are similar, and what metabolic or
physiologic processes are responsible in the pathogenetic pathway leading to
type 2 diabetes.

o The temporal relationship of changes in body weight and body composition,
glucose tolerance, and insulin resistance in the etiology of type 2 diabetes. 
Clinical studies could unravel the sequence of events leading to type 2
diabetes, especially the timing of weight gain with regard to glucose
tolerance and insulin resistance.  A critical question is whether individuals
who will develop diabetes first gain weight and then develop diabetes, with
the same genes leading to both conditions; or whether individuals gain weight
(for genetic or nongenetic reasons) and then proceed to diabetes because of
beta cell defects.

o Beta-cell function.  There is growing appreciation that substantial beta-
cell defects occur prior to the onset of type 2 diabetes.  Very little is
known about the types of defects that actually predict or attend diabetes. 
Most studies that have examined complex aspects of beta-cell function in vivo
have been cross-sectional comparisons of high- vs. low-risk individuals.  A
combination of detailed beta-cell assessments with longitudinal follow-up
would likely yield important information about the pathogenesis of the beta
cell defects.  Other phenotypic traits may also be useful in such studies,
such as beta-cell responses to fatty acids, hyperglycemia, arginine, and
insulin resistance.

o Fat metabolism and insulin resistance.  There is mounting evidence that
altered fat metabolism in the whole body and, possibly, in skeletal muscle or
adipocytes in muscle are important determinants of insulin resistance. 
Longitudinal studies employing detailed assessments of fatty acid turnover
and/or muscle fat metabolism could yield important information about the
relation between fat metabolism and insulin resistance as people change their
physical activity, weight, etc.

o The temporal relationships among the components of Syndrome X.  The
constellation of hypertension, hyperglycemia, obesity, and insulin resistance
is well documented.  However, the temporal development of the individual
components of this syndrome remain to be determined.  In particular, the
etiologic relationships among these components, and their relationship to type
2 diabetes, need further investigation.

o Development of less expensive methods to assess beta cell function and
insulin resistance and development of techniques for measuring underlying
metabolic and physiologic differences among population groups.  For example,
studies could be supported that develop and validate techniques that will more
reliably measure insulin secretion and insulin sensitivity, or evaluate
fatness and fat distribution, for use in future epidemiologic and intervention
studies to reduce risk of type 2 diabetes and risk of diabetes complications.

o Studies to investigate the behavioral, socioeconomic, psychosocial,
cultural, family, and community factors that influence the individualþs risk
for developing type 2 diabetes and how these factors can lead to racial and
ethnic disparities in incidence rates.  A critical question is how prevention
strategies to reduce risk across racial and ethnic groups should incorporate
culturally-specific lifestyle factors.

Advantage might be taken of extant cohort studies that may have been
established for investigation of diabetes or investigation of other diseases. 
A collaboration among investigators of these established cohorts would be
desirable, so that these studies might jointly develop protocols and evaluate
findings.  The results may lead to a proposal to start new cohorts,
appropriately powered, to capture the current risks for development of type 2


It is the policy of the NIH that women and members of minority groups and
their subpopulations must be included in all NIH supported biomedical and
behavioral research projects involving human subjects, unless a clear and
compelling rationale and justification is provided that inclusion is
inappropriate with respect to the health of the subjects or the purpose of the
research.  This policy results from the NIH Revitalization Act of 1993
(Section 492B of Public Law 103-43).  All investigators proposing research
involving human subjects should read the "NIH Guidelines for Inclusion of
Women and Minorities as Subjects in Clinical Research," which was published in
the Federal Register of March 28, 1994 (FR 59 14508-14513) and in the NIH
Guide for Grants and Contracts, Vol. 23, No. 11, March 18, 1994, available on
the web at https://grants.nih.gov/grants/guide/notice-files/not94-100.html.


It is the policy of NIH that children (i.e., individuals under the age of 21)
must be included in all human subjects research, conducted or supported by the
NIH, unless there are scientific and ethical reasons not to include them. 
This policy applies to all initial (Type 1) applications.  All investigators
proposing research involving human subjects should read the "NIH Policy and
Guidelines on the Inclusion of Children as Participants in Research Involving
Human Subjects" that was published in the NIH Guide for Grants and Contracts,
March 6, 1998, and is available at the following URL address:


Applications are to be submitted on the grant application form PHS 398 (rev.
4/98) and will be accepted at the standard application deadlines as indicated
in the application kit.  Application kits are available at most institutional
offices of sponsored research and may be obtained from the Division of
Extramural Outreach and Information Resources, National Institutes of Health,
6701 Rockledge Drive, MSC 7910, Bethesda, MD 20892-7910, telephone 301-
710-0267, email:  GrantsInfo@nih.gov.

The program announcement title and number must be typed on line 2 of the face
page of the application form, and the YES box must be marked.

Applicants planning to submit an investigator-initiated new (type 1),
competing continuation (type 2), competing supplement, or any amended/revised
version of the preceding grant application types requesting $500,000 or more
in direct costs for any year are advised that he or she must contact the NIDDK
program staff before submitting the application, i.e., as plans for the study
are being developed.  The applicant must obtain agreement from the NIDDK
program staff that the NIDDK will accept the application for consideration for
award.  Finally, the applicant must identify, in a cover letter sent with the
application, the staff member who agreed to accept assignment of the
application.  This policy requires an applicant to obtain agreement for
acceptance of both any such application and any such subsequent amendment. 
Refer to the NIH Guide for Grants and Contracts, March 20, 1998 at 

The modular grant concept establishes specific modules in which direct costs
may be requested as well as a maximum level for requested budgets.  Only
limited budgetary information is required under this approach.  The
just-in-time concept allows applicants to submit certain information only when
there is a possibility for an award.  It is anticipated that these changes
will reduce the administrative burden for the applicants, reviewers and
Institute staff.  The research grant application form PHS 398 (rev. 4/98) is
to be used in applying for  these grants, with the modifications noted below.


Modular Grant applications will request direct costs in $25,000 modules, up to
a total direct cost request of $250,000 per year.  Applications that request
more than $250,000 direct costs in any year must follow the traditional PHS
398 application instructions.  The total direct costs must be requested in
accordance with the program guidelines and the modifications made to the
standard PHS 398 application instructions described below:

PHS 398

o  FACE PAGE: Items 7a and 7b should be completed, indicating Direct Costs (in
$25,000 increments up to a maximum of $250,000) and Total Costs [Modular Total
Direct plus Facilities and Administrative (F&A) costs] for the initial budget
period.  Items 8a and 8b should be completed indicating the Direct and Total
Costs for the entire proposed period of support.

4 of the PHS 398.  It is not required and will not be accepted with the

categorical budget table on Form Page 5 of the PHS 398.  It is not required
and will not be accepted with the application.

o  NARRATIVE BUDGET JUSTIFICATION - Use a Modular Grant Budget Narrative page.
(See https://grants.nih.gov/grants/funding/modular/modular.htm for sample
pages.)  At the top of the page, enter the total direct costs requested for
each year.

o  Under Personnel, list key project personnel, including their names, percent
of effort, and roles on the project. No individual salary information should
be provided.

o  For Consortium/Contractual costs, provide an estimate of total costs
(direct plus facilities and administrative) for each year, each rounded to the
nearest $1,000.  List the individuals/organizations with whom consortium or
contractual arrangements have been made, the percent effort of key personnel,
and the role on the project.  Indicate whether the collaborating institution
is foreign or domestic.  The total cost for a consortium/contractual
arrangement is included in the overall requested modular direct cost amount.

o  Provide an additional narrative budget justification for any variation in
the number of modules requested.

o  BIOGRAPHICAL SKETCH - The Biographical Sketch provides information used by
reviewers to assess each individual's qualifications for a specific role in
the proposed project and to evaluate the overall qualifications of the
research team.  A biographical sketch is required for each of the key
personnel, following the instructions below. No more than three pages may be
used for each person.  A sample biographical sketch may be viewed at

- Complete the educational block at the top of the form page
- List current position(s) and any honors
- Provide information, including overall goals and responsibilities, on
research projects ongoing or completed during the last three years
- List selected peer-reviewed publications, with full citations

o  CHECKLIST - This page should be completed and submitted with the
application.  If the F&A rate agreement has been established, indicate the
type of agreement and the date. It is important to identify all exclusions
that were used in the calculation of the F&A costs for the initial budget
period and all future budget years.

o  The applicant should provide the name and phone number of the individual to
contact concerning fiscal and administrative issues if additional information
is necessary following the initial review.

Submit the signed, original, single-sided application, including the
Checklist, along with five signed photocopies and five collated sets of
appendix materials in one package to:

BETHESDA, MD 20892-7710
BETHESDA, MD 20817 (for express/courier service)

The Center for Scientific Review (CSR) will not accept any application in
response to this PA that is essentially the same as one currently pending
initial review, unless the applicant withdraws the pending application.  The
CSR will not accept any application that is essentially the same as one
already reviewed.  This does not preclude the submission of substantial
revisions of applications already reviewed, but such applications must include
an introduction addressing the previous critique.


Applications will be assigned on the basis of established PHS referral
guidelines.  Applications will be evaluated for scientific and technical merit
by an appropriate scientific review group convened in accordance with the
standard NIH peer review procedures.  As part of the initial merit review, all
applications will receive a written critique and undergo a process in which
only those applications deemed to have the highest scientific merit, generally
the top half of applications under review, will be discussed, assigned a
priority score, and receive a second-level review by the appropriate national
advisory council or board.

Review Criteria

The goals of NIH-supported research are to advance our understanding of
biological systems, improve the control of disease, and enhance health.  In
the written comments, reviewer will be asked to discuss the following aspects
of the application in order to judge the likelihood that the proposed research
will have a substantial impact on the pursuit of these goals.  Each of these
criteria will be addressed and considered in assigning the overall score,
weighting them as appropriate for each application.  Note that the application
does not need to be strong in all categories to be judged likely to have major
scientific impact and thus deserve a high priority score.  For example, an
investigator may propose to carry out important work that by its nature is not
innovative but is essential to move a field forward.

o  Significance:  Does this study address an important problem?  If the aims
of the application are achieved, how will scientific knowledge be advanced? 
What will be the effect of these studies on the concepts or methods that drive
this field?

o  Approach:  Are the conceptual framework, design, methods, and analyses
adequately developed, well-integrated, and appropriate to the aims of the
project?  Does the applicant acknowledge potential problem areas and consider
alternative tactics?

o  Innovation:  Does the project employ novel concepts, approaches, or method? 
Are the aims original and innovative?  Does the project challenge existing
paradigms or develop new methodologies or technologies?

o  Investigator:  Is the investigator appropriately trained and well suited to
carry out this work?  Is the work proposed appropriate to the experience level
of the principal investigator and other researchers (if any)?

o  Environment:  Does the scientific environment in which the work will be
done contribute to the probability of success?  Do the proposed experiments
take advantage of unique features of the scientific environment or employ
useful collaborative arrangements?  Is there evidence of institutional

In addition to the above criteria, in accordance with NIH policy, all
applications will also be reviewed with respect to the following:

o  Adequacy of plans to include both genders, minorities and their subgroups,
and children as appropriate for the scientific goals of the research.  Plans
for the recruitment and retention of subjects will also be evaluated.

o  The reasonableness of the proposed budget and duration to the proposed

o  The adequacy of the proposed protection of humans, animals, or the
environment, to the extent that they may be adversely affected by the project
proposed in the application.


Applications will compete for available funds with all other recommended
applications assigned to the National Institute of Diabetes and Digestive and
Kidney Diseases.  The following will be considered in making funding

o  Quality of the proposed project as determined by peer review
o  Availability of funds
o  Program priority


Inquiries are encouraged.  The opportunity to clarify any issues or questions
from potential applicants is welcome.

Direct inquiries regarding scientific issues to:

Maureen I. Harris, PhD, MPH
Division of Diabetes, Endocrinology, and Metabolic Diseases
National Institutes of Diabetes and Digestive and Kidney Diseases
Building 45, Room 5AN24
Bethesda, MD 20892
Telephone:  301-594-8801
FAX:  301-480-3503
Email:  harrism@extra.niddk.nih.gov

Direct inquiries regarding fiscal and administrative matters to:

Denise Payne
Division of Extramural Activities
National Institutes of Diabetes and Digestive and Kidney Diseases
Building 45, Room 6AS49
Bethesda, MD 20892-6600
Telephone:  (301) 594-8845
FAX: (301) 480-3504


This program is described in the Catalog of Federal Domestic Assistance No.
93.847.  Awards are made under authorization of the Public Health Service Act,
Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC
241 and 285) and administered under NIH grants policies and Federal
Regulations 42 CFR 52 and 45 CFR Parts 74 and 92.  This program is not subject
to the intergovernmental review requirements of Executive Order 12372 or
Health Systems Agency review.

The PHS strongly encourages all grant and contract recipients to provide a
smoke-free workplace and promote the non-use of all tobacco products.  In
addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking
in certain facilities (or in some cases, any portion of a facility) in which
regular or routine education, library, day care, health care or early
childhood development services are provided to children.  This is consistent
with the PHS mission to protect and advance the physical and mental health of
the American people.

Return to Volume Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.